JOHN V. WALLER, M.D.
Disabling and severe anemia occurs frequently in persons who have epistaxis from congenital hemorrhagic telangiectasia. Repeated epistaxis in this disease defied treatment until Koch et al.,1 in August, 1952, described suppression of recurrent epistaxis following the use of oral estrogens. In addition to the beneficial effect on the bleeding, these investigators noted that the atrophic nasal mucosa became pink, moist and soft. The patient reported in this communication had an initial excellent result, with severe exacerbation after seven months of continuous treatment.
A 57 year old white male was admitted to the Lenox Hill Hospital on January 25,
Learn more about subscription options.
Register Now for a free account.
WALLER JV. HEMORRHAGIC TELANGIECTASIA TREATED WITH STILBESTROL(HEMORRHAGIC TELANGIECTASIA TREATED WITH STILBESTROL*). Ann Intern Med. 1956;44:204–206. doi: 10.7326/0003-4819-44-1-204
Download citation file:
Published: Ann Intern Med. 1956;44(1):204-206.
Hematology/Oncology, Red Cell Disorders.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only